Mersana Therapeutics - Q2 2025

Executive Summary

• Q2 2025 results were in line on EPS (per S&P “Primary EPS”) but missed materially on revenue vs consensus; collaboration revenue was $3.06M vs $6.06M consensus and net loss was $24.3M; cash/equivalents were $77.0M with runway into mid-2026, aided by cost actions and July debt payoff.
• Strategic progress: >45 patients enrolled across two Emi‑Le post‑topo‑1 TNBC expansion cohorts; management reiterated initial expansion data in 2H 2025 and highlighted encouraging efficacy signals in B7‑H4‑high TNBC and ACC‑1 from prior datasets.
• Corporate actions: 1‑for‑25 reverse split effective July 25; Nasdaq bid price compliance regained; ~$17.9M debt repaid in July; $15M GSK milestone achieved in July (payment due in Q3).
• Stock reaction catalysts near term: 2H 2025 Emi‑Le expansion readout (dose A vs B, durability with proteinuria mitigation), initial pharmacodynamic STING activation data for XMT‑2056, and regulatory dialogue on potential randomized design in post‑topo‑1 TNBC.

What Went Well and What Went Wrong

What Went Well

• Emi‑Le clinical momentum and enrollment: >45 TNBC patients enrolled across two expansion cohorts; initial expansion data targeted for 2H 2025. CEO: “We look forward to reporting initial clinical data from these expansion cohorts later this year.”
• Compelling prior signals in target populations: B7‑H4‑high, post‑topo‑1 TNBC showed 29% ORR and median PFS ~16 weeks at intermediate doses; ACC‑1 cohort showed 56% ORR as of Mar 8 cutoff in dose‑escalation/backfill data.
• Balance sheet de‑risking and visibility: Cash/equivalents $77.0M at 6/30; debt fully repaid in July; runway into mid‑2026; $15M GSK milestone achieved in July (payable in Q3).

What Went Wrong

• Revenue miss and continued operating losses: Q2 collaboration revenue $3.06M (y/y +33%) but below consensus; net loss ($24.3M) flat y/y despite restructuring expenses ($3.9M).
• Restructuring charges and opex headwinds: $3.9M restructuring expense in Q2 tied to workforce reduction (55% announced in May) to focus on Emi‑Le; R&D $16.2M and G&A $7.4M remain meaningful vs small revenue base.
• Safety/operational risk to monitor: proteinuria mitigation and treatment interruptions remain a focal point; management expects 2H data to address ability to keep patients on therapy at higher dose B.

Transcript

Operator (participant)

Good morning and welcome to Mersana Therapeutics' Second Quarter 2025 Financial Results and Business Updates Conference Call and Webcast. Currently, all participants are in listen-only mode. There will be a question and answer session at the end of this call. Please note this call is being recorded. I would now like to turn the call over to Jason Fredette, Senior Vice President, Investor Relations and Corporate Communications.

Jason Fredette (SVP of Investor Relations and Corporate Communications)

Thank you, operator, and good morning, everyone. Before we begin, please note that this call will contain forward-looking statements within the meaning of federal securities laws. These statements may include, but are not limited to, those related to the potential clinical benefits of our product candidates and platforms, our clinical trial progress and design, addressable market opportunities, anticipated clinical milestones and data presentations, and cash runway. Each of these forward-looking statements is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements. These risks and uncertainties are discussed in our quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 15th 2025, and in subsequent SEC filings. Our filings are available at sec.gov and on our website, mersana.com.

Except as required by law, we assume no obligation to update forward-looking statements publicly, even if new information becomes available in the future. On today's call, we have Mersana's Chief Executive Officer, Dr. Marty Huber, and our Chief Operating Officer and Chief Financial Officer, Brian DeSchuytner. With that, let me turn the call over to Marty to begin the discussion.

Marty Huber (CEO)

Thank you, Jason, and good morning, everyone. The second quarter of 2025 was eventful for Mersana, particularly as it relates to Emi-Le, our Dolasynthen ADC targeting B7-H4. Chief among the highlights were our oral presentations at ASCO 2025 and ESMO Breast Cancer 2025, and the strong enrollment progress we made in our expansion cohorts. At ASCO in Chicago, Dr. Erika Hamilton of the Sarah Cannon Research Institute presented data as of March 8th data cutoff across all patients who enrolled in our Emi-Le phase I dose escalation and backfill cohorts. Safety and tolerability remained consistent with previously reported data. This presentation also included clinical activity data across all enrolled B7-H4-expressing tumors.

At intermediate doses ranging from about 38 mg/m2-67 mg/m2, the confirmed objective response rate, or ORR, was 31% among the evaluable patients with B7-H4 high tumor expression, which we initially defined as a tumor proportion score of 70% or higher. The presentation also highlighted some intriguing activity that we have seen in adenoid cystic carcinoma type 1, or ACC1. This is a rare head and neck cancer with a very poor prognosis and no approved therapies. In the past, other development candidates, such as VEGF TKIs and NOTCH inhibitors, have investigated this tumor type and have shown response rates ranging from the mid-single digits to the mid-teens. Among the nine evaluable patients with ACC1 who received any dose of Emi-Le, regardless of B7-H4 expression, we observed four confirmed responses and one unconfirmed objective response.

Subsequent to the March 8th cutoff, that one [UpRi] was confirmed for an objective response rate in ACC1 of 56%. In recent months, we have enrolled additional patients with ACC1 in backfill cohorts. While these data help to demonstrate Emi-Le's broader development potential, our focus today is on addressing the significant unmet needs of patients with triple-negative breast cancer, or TNBC, who have previously been treated with a topoisomerase-1 inhibitor, or topo-1 ADC, such as TRODELVY, ENHERTU, or DATROWAY. The standard of care today for these patients is single-agent chemotherapy, and unfortunately, their expected outcomes are exceedingly poor. Based on reported data from the original ASCENT phase III trial of TRODELVY in topo-1 naive patients with recurrent metastatic TNBC, the objective response rate, or ORR, for single-agent chemotherapy was 5%. Progression-free survival, or PFS, was 1.7 months, and overall survival, or OS, was 6.7 months.

At the ESMO Breast Cancer Congress in Munich, Germany, Dr. Hamilton presented data as of that same March 8th cutoff from patients with TNBC who had received intermediate doses of Emi-Le, highlighting patients who had received one to four prior lines of treatment. Nearly all of these patients also had received at least one previous topo-1 ADC. Among the patients with B7-H4 low TNBC who received an intermediate dose of Emi-Le, observed clinical activity resembled today's standard of care, with an ORR of 0%, a median PFS of 6.4 weeks, and a median OS of 5.7 months.

Among those patients we have initially characterized as B7-H4 high TNBC who received an intermediate dose of Emi-Le, the ORR was 29%, the median PFS was 16 weeks, and the median OS had not yet been reached as of the data cutoff. It is data like these that led us to initiate dose expansion, and in recent months, we have continued to make progress in this phase of development. In expansion, we are enrolling patients with TNBC who have received one to four prior lines of treatment in the metastatic setting, including at least one prior topo-1 ADC. We are investigating two Emi-Le dosing regimens.

Our dose A cohort is receiving a 67.4 mg/m2 dose of Emi-Le every four weeks, and our dose B cohort is receiving 80 mg/m2 dose of Emi-Le every four weeks following a loading dose of 44.5 mg/m2 on days one and eight of the first four-week cycle. Collectively, we have enrolled more than 45 patients across these two cohorts, and we remain on track to report initial clinical data from expansion in the second half of 2025. Finally, on the Emi-Le front, we are often asked how big the post-topo-1 TNBC opportunity is. We believe it is sizable, and it has the potential to get substantially larger. As a reminder, today, topo-1 ADCs with TNBC indications are only approved in the recurrent setting. Despite this, TRODELVY is already expected to generate about $1 billion in global TNBC revenues in 2025.

This figure does not include revenues that other topo-1 ADCs are generating in this setting, nor does it consider how the opportunity would increase as these agents move into early lines of therapy. For example, we believe the recent positive readouts of ASCENT-03 and ASCENT-04 will make TRODELVY the new frontline standard of care for patients with TNBC, which will greatly increase the post-topo-1 population of patients. As a reminder, emerging clinical data suggests that once a patient receives an initial topo-1 ADC, a subsequent topo-1 agent has substantially reduced benefit due to payload resistance. We believe this evolving treatment landscape opens the opportunity for a novel non-topo-1 agent like Emi-Le to address the growing unmet need for topo-experienced patients if it is approved. If a patient receives TRODELVY in the frontline, Emi-Le could potentially be used as a second-line therapy.

If a patient receives another topo-1 ADC, such as ENHERTU, Dato-DXd, or Sac-TMT in the recurrent setting, Emi-Le could potentially be used subsequent to that. Additionally, because of Emi-Le's differentiated tolerability profile, we believe it could potentially be explored in combinations with other agents, including topo-1 ADCs, platinum chemotherapy, and PD-L1 agents. Let's move on to XMT-2056, Mersana's Immunosynthin ADC targeting HER2. As a reminder, GSK has an exclusive global license option to co-develop and commercialize this candidate. XMT-2056 is in the dose escalation portion of our phase I clinical trial, which is enrolling patients with a variety of HER2-expressing tumors. We are pleased to report that in July, we achieved a $15 million development milestone under our agreement with GSK. Payment of this development milestone is due later this quarter. With that, let's turn the call over to Brian for our financial review.

Brian DeSchuytner (COO and CFO)

Thank you, Marty. Beginning with our balance sheet, we ended the second quarter of 2025 with $77 million in cash and cash equivalents. Net cash used in operating activities for the second quarter of 2025 was $22.6 million, which included $2.4 million in severance-related payments. In July, we paid approximately $17.9 million to pay off our debt facility. We continue to expect that our capital resources will enable us to support our current operating plan commitments into mid-2026. Please note that our cash runway guidance does not assume the receipt of any future milestone payments from our current collaborations or proceeds that we may realize from future collaborations. Collaboration revenue for the second quarter of 2025 was $3.1 million, compared to $2.3 million for the same period in 2024.

The year-over-year change was primarily related to increased revenue recognized under our collaboration and license agreements with J&J and Merck KGaA, partially offset by reduced revenue recognized under our agreement with GSK. Research and development expenses for the second quarter of 2025 were $16.2 million, compared to $17.2 million for the same period in 2024. For the most recent quarter, approximately $900,000 of this spending was related to non-cash stock-based compensation. The year-over-year change in R&D expense was primarily related to lower headcount and related employee compensation costs, which were partially offset by an increase in costs related to Emi-Le and XMT-2056 clinical development activities and manufacturing activities associated with the company's collaborations. General and administrative expenses for the second quarter of 2025 declined to $7.4 million, compared to $10.5 million during the same period in 2024.

Approximately $1.1 million in non-cash stock-based compensation expenses were included in G&A for the most recent quarter. The year-over-year change in G&A was primarily related to lower headcount and related employee compensation costs and a reduction in consulting and professional services fees. During the second quarter, we incurred $3.9 million in restructuring charges related primarily to severance and benefit payments, outplacement services, and related expenses. Finally, Mersana's net loss for the second quarter of both 2025 and 2024 was $24.3 million. That concludes our business update. Operator, would you please open the call to questions from the audience?

Operator (participant)

We will now begin the question and answer session. To ask a question, you may press star, then one on your touchtone phone. To withdraw your question, please press star, then two. At this time, we'll pause momentarily to assemble our roster. The first question comes from Tara Bancroft with TD Cowen. Please go ahead.

Tara Bancroft (Director and Senior Biotech Equity Research Analyst)

Hi, good morning, everyone. My question is, for the data that are coming in imminently in the second half, can you help us set expectations for what will actually be in the data, like maybe the minimum amount of follow-up that we should expect from patients that are enrolled and if all of the 45 that are enrolled are going to be included in that data set and/or available, and what benchmarks that you would want to meet or beat? Thanks so much.

Marty Huber (CEO)

Thank you, Tara. Good morning. There was a lot there. Let me try to walk through each of those. Once again, we've now enrolled over 45 patients. We would expect that group of patients to be the basis of the data, but we'll have to be a little careful about committing to an exact number because we have to treat the patients, get through it, get scans, et cetera. With regards to dose A and B, the one thing I would remind you is it's going to include both dose A and dose B. Just to remind you, dose A started at the beginning of the year. Dose B, as we announced in May, we had started enrolling patients in dose B.

The one point I would make is that the duration of follow-up will be longer on dose A than dose B, but you should have sufficient data on dose B to understand efficacy, safety, durability, et cetera. You will get, and you will be able to, your standard presentation like we've done before. The final part of that is just to remind you, these are all patients, and we would generally expect that about 40%-50% of them will be in the B7-H4 high bucket.

Tara Bancroft (Director and Senior Biotech Equity Research Analyst)

Okay, got it. I know you don't typically set expectations for efficacy, but maybe just a good benchmark for what you think would be a good result.

Marty Huber (CEO)

I think, you know, just to remind you that the efficacy for the standard of care in this setting is a 5% response rate and a six to seven-week PFS. Like the data we shared at Munich, we would think that's kind of the minimum bar that if you have the 16 weeks and you have a response rate in the 20s, you're going to, we believe that you would beat the standard of care in a randomized trial fairly readily. Better than that is obviously better, but I think that's kind of the minimum bar that we feel confident moving forward with.

Tara Bancroft (Director and Senior Biotech Equity Research Analyst)

Okay, great. Thank you for that. That's very helpful.

Operator (participant)

Your next question comes from Jonathan Chang with Leerink. Please go ahead.

Speaker 9

Hey, this is [Ewan Ong] for Jonathan. Thanks for taking our questions and congrats on the enrollment progress. Can you just provide more color on the implementation of the proteinuria mitigation strategies in the dose expansion cohorts? Thank you.

Marty Huber (CEO)

Sure. Just to remind people, Amendment 5 was put in place at the beginning of this year. What we did in Amendment 5 was, one, we implemented a prospective, in other words, routinely starting in patients either an ACE inhibitor or an ARB before they even, I mean, at the beginning of treatment. The idea was to try to minimize the development of proteinuria. The major change, however, was since we had observed that the proteinuria was primary albuminuria, isolated albuminuria, in the absence of changes in serum creatinine or serum albumin, with the consultation with our onconephrologist, the protocol amendments allow to continue to treat patients as opposed to interrupting treatment because previously we'd had this kind of protocol-mandated interruption.

What we will be able to present you data on is with the updated data set for dose B, is at the higher dose, have we been effective in preventing those treatment delays?

Speaker 9

Very helpful. Thank you.

Operator (participant)

Again, if you have a question, please press star, then one. The next question comes from Charles Zhu with LifeSci Capital. Please go ahead.

Charles Zhu (Managing Director and Senior Research Analyst)

Hey, good morning, everyone. Thanks for the call and congratulations on the updates and the enrollment across the board. A couple from me. Wanted to confirm if you've settled in on this TPS of 70 as a B7-H4 high versus a low cutoff. Maybe as a follow-up to the prior question, with respect to the proteinuria mitigation, how would you evaluate, like between those two doses if we're talking about something like what kind of a delta in clinical profile, I guess, would justify the additional step of undergoing mitigation steps to go for the more efficacious as opposed to a less efficacious dose? Thank you.

Marty Huber (CEO)

With regards to your first question, the expansion data set will be part of the data set that we use in finalizing the cut point. I think suffice it to say, even if the TPS score moves a little bit, we fully anticipate, based on the literature and our initial backfill and escalation data, that we're talking 40%-50% of the patient population, even if the actual TPS score to define that population changes a little. We haven't locked in on TPS 70 today, but that'll be something that we'll use this data set to do. Excuse me. With regards to proteinuria, ultimately, our hypothesis that came forward out of our initial data set was that these higher doses were resulting in more patients having more than a 30% reduction or getting that initial [UpRi].

Our core hypothesis is that if you don't have the treatment interruptions and more patients are getting a reduction in the tumor, ultimately that will lead to a better outcome for patients, more responses or better PFS, etc. What we will be looking for in B is that we are able to maintain patients on drug and that will give us better efficacy. If that efficacy trade-off is not good enough, then dose A would be the go-forward dose. That's a data-driven decision that we'll take. In fact, these data are a critical part of that decision process. We need to get the dose A and dose B data fully in hand.

Charles Zhu (Managing Director and Senior Research Analyst)

Understood. Thank you for taking the questions, and congrats again.

Operator (participant)

Your next question comes from Michael Schmidt with Guggenheim. Please go ahead.

Michael Schmidt (Senior Biotech Analyst and Senior Managing Director)

Hey, good morning. Thanks for taking my questions. Just a couple of follow-ups on the expansion cohorts. Did you say roughly how many patients would be in dose cohort A versus B for this upcoming update in the second half? What type of venue are you planning to do this at? I have a follow-up.

Marty Huber (CEO)

I'll answer the venue question first. With regards to the venue, we have not stated whether this will be a corporate company presentation or a scientific meeting. That's a decision that will be TBD. With regards to how many patients are in each, we haven't provided that degree of specificity, but we'll note that we've been enrolling the dose B patients now for several months. I think suffice it to say there should be a reasonable number of patients at both doses. The only major difference will be the duration of follow-up will be shorter for the dose B patients than dose A patients.

Michael Schmidt (Senior Biotech Analyst and Senior Managing Director)

Makes sense. Thanks. A question just on possible next steps as we think about potential phase III study in TNBC. In terms of trial design, should we think about a study that may look similar to the ASCENT study perhaps? Would you limit enrollment to topo-1 ADC-exposed patients only or also allow naive patients? If so, why not? Why wouldn't you include naive patients as well? Your estimation in terms of what percantage of patients do you think are topo-1 ADC-exposed in the third line and later setting at this point? Thanks.

I think I'll take the last one first on the topo-exposed. To be frank, whether we allow the topo naive or not is sort of a moot point in second or third line TNBC in the United States today because if you, as you recall from our demographics, almost all of our patients had seen a prior topo. I think that makes it, once again, the detail of do you allow them becomes kind of irrelevant because from a standard of care point of view, they're all going to have received them, or almost all. With regard, and I think as we see the ASCENT-03 and 04 data come out, that's going to even increase because now they're going to get them first line. I think the big change we'll see is there's going to be second line patients that historically would be just getting a topo.

The second line patients now will be post-topo. Our ideal, so one of the reasons why do you say post-topo is a couple of things. One, we have a fast-track designation in post-topo breast cancer. The way our fast-track designation reads, it actually allows you to get a little broader than classic TNBC because remember you have the, if you just remind you, we have the HER2 lows. If they've seen like in HER2, that counts. Obviously, all of this is a discussion with the agency, but we think kind of we have this unique opportunity in this post-topo setting based on the unique properties of our platform. This is kind of an easy space just to go into given that most patients are going to be in this space anyway.

Maybe just to follow up, is there an opportunity to perhaps do a study that includes patients beyond the classic TNBC definition, including, for example, HER2 low patients into the same study to expand the opportunity?

Marty Huber (CEO)

I think that's one of the advantages of doing a randomized trial because you'll have a control arm. The agent, once again, we have no agency conversations yet on this. If you think about it, one of the advantages, one of the limitations, for example, if you do a single arm, you have to make sure that every patient that enrolls has seen every potential prior therapy. If you go into a randomized trial, you can be a little looser on that because the control arm will account for that. We do think doing a randomized trial, you can do it pretty much just as fast because your PFS endpoint, your control arm is in six weeks. You also get your survival data, you avoid doing a confirmatory trial, and by the way, you might be able then to broaden out your population exactly as your suggestion.

Michael Schmidt (Senior Biotech Analyst and Senior Managing Director)

Great. Thank you.

Operator (participant)

Your next question comes from Colleen Kusy with Baird. Please go ahead.

Speaker 10

Hey, good morning. This is Nick on calling. Thanks for taking our questions. Just wanted to ask for Emi-Le, can you comment on how the rate of enrollment is going versus your expectations and whether you plan on opening any additional sites for the expansion? I had a follow-up after that. Thanks.

Marty Huber (CEO)

Right now it's going very well. I think for a TNBC population at a limited number of sites, getting 45 patients who are, you know, these are patients who we're having to get biomarker data on. These are all patients who have to get a tissue result, test fit, et cetera. Had to have had a prior topo, be one to four prior lines. I think we're very pleased with the outcome of the enrollment. We don't envision needing additional sites to finish expansion. Certainly as we move into a pivotal though, we're going to want to expand to a broader population.

Speaker 10

Great, thank you. Moving to XMT-2056, I know you commented earlier that enrollment had been a little slower due to some competition in the area. Can you comment on how the enrollment's going there as well, and if you have a decision on which indication to go in with that readout?

Marty Huber (CEO)

We haven't selected obviously an indication for XMT-2056, other than it's HER2 positive cancers. I think one of the reasons we are very, very pleased to discuss the $15 million milestone is this is a program that's been very, very quiet and we hadn't had a lot of progress. In fact, we were in our last call kind of downplaying the enrollment a little bit. It picked up and we made our milestone. In our view, it's chugging along. I think we're still maintaining our guidance that we'd like, you know, we're not committing to sharing dose escalation data this year. We are hoping to share some data, pharmacodynamic data showing that the mechanism of action is in fact working in patients.

Speaker 10

Great, thank you so much.

Operator (participant)

Again, if you have a question, please press star, then one. Your next question comes from Andy Hsieh with William Blair. Please go ahead.

Andy Hsieh (Biotech Research Analyst)

Thanks for taking our questions. I think you have a couple of months of experience in terms of the trial protocol change to address proteinuria. I'm curious if you have heard from investigators any feedback regarding the change and potential improvement to allow patients to stay on therapy. That's question number one. Question number two, just kind of housekeeping, maybe a follow-up to the previous question. The $15 million milestone payment, is that completely progress-based or can we glean into potential, you know, promising efficacy there as well? Thank you.

Marty Huber (CEO)

I'm going to answer the question on Emi-Le, then I'm going to turn it over to Brian to talk about the criteria for the $15 million. With regards to the proteinuria, all we can say is that enrollment's continuing at dose B. The investigator enthusiasm remains high, and we're looking forward to sharing the data.

Brian DeSchuytner (COO and CFO)

With respect to the milestone, it's a development milestone, but unfortunately, we can't get into additional detail on that. It remains confidential.

Andy Hsieh (Biotech Research Analyst)

That's helpful. Thank you.

Operator (participant)

Your next question comes from Asthika Goonewardene with Truist. Please go ahead.

Asthika Goonewardene (Managing Director and Senior Biotech Analyst)

Good morning guys, and thanks for taking my questions. Marty, I think you hit the nail on the head with the whole idea of dose B and trying to see if you're able to keep the patients on therapy longer, which I think is exactly what you need to be doing with an ADC here. Let me ask you this. When you present the data or announce the data later on this year, do you think you'll have that question answered, i.e., does with the prophylaxis and everything going into play that you are able to keep the patients on therapy longer on dose level B? Will that be answered this year? I have a couple of follow-ups.

Marty Huber (CEO)

Yeah, while dose B will have more limited durability, I think, just to remind you, we were seeing the treatment interruptions in cycle two and cycle three. We're confident that we'll have sufficient data to at least answer that, show the difference between what was happening at the higher doses pre-Amendment 5 versus with the new proteinuria mitigation strategy. I think we're pretty confident in our second half data display. We should be able to answer that question.

Asthika Goonewardene (Managing Director and Senior Biotech Analyst)

Got it. Excellent. Just a technicality here. What proportion of the TNBC patients that you recruited have actually seen ENHERTU? How do you see that play out as you're thinking about recruiting a pivotal study? Obviously, we're going to get TRODELVY in that frontline setting impacting here, but do you think you'll see patients who've seen both TRODELVY as well as ENHERTU?

Marty Huber (CEO)

Just to remind you, in our initial demographics that we presented previously, a quarter of patients had both. I mean, think about that. I think it was 27% of patients that had seen both TRODELVY and ENHERTU. Now, is that going to be the exact same in our study going forward? It may be a little lower because what we suspect, given the limited outcomes with that strategy, if we have a pivotal study open that allows patients who go on whether they've had either TRODELVY or ENHERTU, we think a fair amount of those patients who come in with the HER2 low will then have an opportunity to get the ENHERTU and then go on to our trial. Once again, this is something that will be part of the details of study design when we engage with regulatory authorities. That is certainly something we are entertaining.

Asthika Goonewardene (Managing Director and Senior Biotech Analyst)

Got it. Thanks. We talked a little bit about, you know, other breast cancer indications. Let me ask you this point blank, Marty. The next steps and going into a pivotal study, will you be kind of maybe focusing exclusively on TNBC, or do you want to do some more work to get some of these other areas of breast cancer, maybe the HER2 lows, generate some more data on that and also kick off a pivotal study that encompasses that patient population as well? Thanks, guys.

Marty Huber (CEO)

We would love to do additional activities, including hormone receptor-positive breast cancer. I think there are opportunities to study that. At this point in time, given our current kind of data and capital constraints, we are focused on TNBC. What I want to remind you is in our fast-track designation, it's not limited to TNBC. It does include these HER2 lows. I think we have to think about it. This is where we probably need to just think about the population a little different instead of a classic TNBC. In a way, we're thinking of as post-topo breast cancer is actually kind of a wider population than just TNBC. This will be a critical part of our discussion of the details of design. We do have data in these HER2 low post-in HER2 patients. This will be something to look forward to.

Operator (participant)

This concludes our question and answer session. I would like to turn the conference back over to Dr. Marty Huber for any closing remarks.

Marty Huber (CEO)

Thank you, operator, and thanks everyone for dialing in. We hope you enjoy the end of the summer. That concludes our call, operator.

Operator (participant)

The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.